UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2011
MARCH 31, 2012

OR

o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE TRANSITION PERIOD FROM __________ TO _________

COMMISSION FILE NUMBER: 000-25132

MYMETICS CORPORATION
(Exact name of registrant as specified in its charter)
 
DELAWARE  25-1741849
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
 
c/o Mymetics S.A.
Biopole
Route de la Corniche, 4
1066 Epalinges (Switzerland)
 
(Address                        (Address of principal executive offices)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: 011 41 21 653 4535
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
COMMON STOCK, $0.01 PAR VALUE
(Title of Class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x           No o
             
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x          No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “accelerated filer,” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 Large Accelerated Filer oAccelerated Filer o
   
 Non-Accelerated Filer oSmaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes o         No x
                                             
Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date:
 
Class Outstanding at November 14, 2011May 11, 2012
Common Stock, $0.01 par value 255,505,888295,318,813
 
 
 
 
 
PART I.    FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MYMETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(IN THOUSANDS OF EUROS)

 March 31,  December 31, 
 September 30,  December 31,  2012  2011 
 2011  2010       
ASSETS            
Current Assets            
Cash E639  E1,811  E619  E382 
Receivable officer  --   13 
Receivable other  40   87   52   61 
Prepaid expenses  58   30   54   54 
Total current assets  737   1,941   725   497 
                
Property and equipment, net of accumulated depreciation of E255 at September 30, 2011 and E212 at December 31, 2010  34   76 
License contract, net of accumulated amortization of E337 at December 31, 2010  --   2,357 
Property and equipment, net of accumulated depreciation of E276 at March 31, 2012 and E239 at December 31, 2011  37   49 
In-process research and development  2,266   2,266   2,266   2,266 
Goodwill  6,671   6,671   6,671   6,671 
 E9,708  E13,311  E9,699  E9,483 
                
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)                
Current Liabilities                
Accounts payable E1,109  E1,340  E1,203  E1,025 
Taxes and social costs payable  2   26   2   2 
Current portion of notes payable to related parties, net of unamortized debt discount of NIL at September 30, 2011 and E600 at December 31, 2010  6,239   3,872 
Current portion of notes payable to related        
Parties  5,810   5,711 
Total current liabilities  7,350   5,238   7,015   6,738 
                
Convertible notes payable to related parties, less current portion  24,833   23,510   25,765   25,331 
Convertible note payable – other  --   2,718 
Acquisition-related contingent consideration  5,795   3,212   6,547   5,753 
Total liabilities  37,978   34,678   39,327   37,822 
                
Shareholders' Equity (Deficit)                
Common stock, U.S. $.01 par value; 495,000,000 shares authorized; Issued 255,505,888 at September 30, 2011 and 213,963,166 at December 31, 2010  2,177   1,888 
Common stock, U.S. $.01 par value; 495,000,000 shares authorized; issued 295,318,813 at March 31, 2012 and 276,017,339 at December 31, 2011  2,468   2,322 
        
Preferred stock, U.S. $.01 par value; 5,000,000 shares authorized; none issued or outstanding  --   --   --   -- 
Additional paid-in capital  31,702   29,602   33,766   32,732 
Deficit accumulated during the development stage  (62,835)  (53,518)  (66,524)  (64,057)
Accumulated other comprehensive income  686   661   662   664 
  (28,270)  (21,367)  (29,628)  (28,339)
 E9,708  E13,311  E9,699  EE 9,483 

The accompanying notes are an integral part of these financial statements.

 
 
 
 
MYMETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(IN THOUSANDS OF EUROS)EUROS, EXCEPT FOR PER SHARE AMOUNTS)
 
       TOTAL ACCUMULATED 
 FOR THE THREE  FOR THE THREE  DURING THE 
 
FOR THE THREE
MONTHS ENDED SEPTEMBER 30, 2011
  
FOR THE
 THREE
MONTHS ENDED SEPTEMBER 30, 2010
  
TOTAL ACCUMULATED
DURING THE
DEVELOPMENT STAGE
AS OF SEPTEMBER 30, 2011
  MONTHS ENDED  MONTHS ENDED  DEVELOPMENT STAGE 
          MARCH 31, 2012  MARCH 31, 2011  AS OF MARCH 31, 2012 
Revenue                  
Sales E 75    38  E 660  E  --  E 37  E 660 
Interest  1   1   41   --   1   42 
Gain on extinguishment of debt  --   --   774   --   --   774 
Gain on sales of equipment  --   --   69   --   1   69 
Government grants  34   --   116   --   --   107 
  110   39   1,660   --   39   1652 
Expenses                        
Research and development  173   978   24,671   786   440   25,878 
General and administrative  522   1,273   22,669   368   416   23,213 
Bank fee  --   --   940   2   1   943 
Induced conversion cost  --   807   807   --   -   807 
Interest  535   784   9,051   529   819   10,156 
Change in the fair value of acquisition-related contingent consideration  (432)  642   2,245   794   --   2,997 
Goodwill impairment  --   --   209   --   --   209 
Depreciation  16   52   770   12   14   796 
Amortization of intangibles  48   49   481   --   48   481 
Impairment of license contract  2,213   --   2,213   --   --   2,213 
Directors' fees  5   5   351   8   5   372 
Other  68   --   66   (32)  (8)  88 
  3,148   4,590   64,473   2,467   1,735   68,153 
Loss before income tax provision  (3,038)  (4,551)  (62,813)  (2,467)  (1,696)  (66,501)
Income tax provision  --   --   (22)  --   (4)  (23)
Net loss  (3,038)  (4,551)  (62,83)  (2,467)  (1,700)  (66,524)
Other comprehensive income (loss)                        
Foreign currency translation adjustment  26   (9)  686   (2)  -5   662 
Comprehensive loss E(3,012)  E(4,560)  E(62,149)  E (2,469) E (1,705) E (65,862 )
Basic and diluted loss per share EE(0.01)  E(0.02)      E (0.01) E (0.01)     
 
The accompanying notes are an integral part of these financial statements.

 
 
 

MYMETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(IN THOUSANDS OF EUROS)
   
FOR THE THREE
MONTHS ENDED SEPTEMBER 30, 2011
   
FOR THE
 THREE
MONTHS ENDED SEPTEMBER 30, 2010
  
TOTAL ACCUMULATED
DURING THE
DEVELOPMENT STAGE
AS OF SEPTEMBER 30, 2011
 
Revenue         
Sales E 150  E 113  E 660 
Interest  2   3   41 
Gain on extinguishment of debt  --   --   774 
Gain on sales of equipment  1   --   69 
Government grants  34   --   116 
   187   116   1,660 
Expenses            
Research and development  922   2,239   24,671 
General and administrative  1,344   2,646   22,669 
Bank fee  2   1   940 
Induced conversion cost  --   807   807 
Interest  2,183   2,006   9,051 
Change in the fair value of acquisition-related contingent consideration  2,583   825   2,245 
Goodwill impairment  --   --   209 
Depreciation  43   91   770 
Amortization of intangibles  144   145   481 
Impairment of license contract  2,213   --   2,213 
Directors' fees  15   15   351 
Other  55   1   66 
   9,504   8,776   64,473 
Loss before income tax provision  (9,317)  (8,660)  (62,813)
Income tax provision  --   --   (22)
Net loss  (9,317)  (8,660)  (62,835)
Other comprehensive income (loss)            
Foreign currency translation  adjustment  25   (26)  686 
Comprehensive loss E(9,292)  E(8,686)  E(62,149) 
Basic and diluted loss per share E(0.04)  E(0.04)     

The accompanying notes are an integral part of these financial statements.
MYMETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(IN THOUSANDS OF EUROS)
 
        TOTAL ACCUMULATED 
  FOR THE THREE  FOR THE THREE  DURING THE 
  MONTHS ENDED  MONTHS ENDED  DEVELOPMENT STAGE 
  MARCH 31, 2012  MARCH 31, 2012  AS OF MARCH 31, 2012 
Cash Flow from Operating Activities         
Net loss E(2,467) E(1,700) E(66,524)
Adjustments to reconcile net loss to net cash used in operating activities            
Change in the fair value of acquisition-related contingent consideration  794   --   2,997 
Depreciation  12   14   796 
Amortization of intangibles  --   48   481 
Impairment of license contract  --   --   2,213 
Goodwill impairment  --   --   209 
Fees paid in warrants  --   --   223 
Gain on sales of equipment  --   (1)  (69)
Gain on extinguishment of debt  --   --   (774)
Services and fee paid in common stock  --   --   5,403 
Stock compensation expense – options  15   29   339 
Amortization of debt discount  --   300   1,410 
Induced conversion cost  --   --   807 
Warrant modification cost  --   --   484 
Changes in operating assets and liabilities,            
Receivables  9   (122)  18 
Accounts payable  178   (136)  1,784 
Taxes and social costs payable  --   (24)  2 
Other  --   (3)  (9)
Net cash used in operating activities  (1,459)  (1,595)  (50,210)
             
Cash Flows from Investing Activities            
Patents and other  --   --   (393)
Proceeds from sale of equipment  --   4   137 
Purchase of property and equipment  --   --   (280)
Acquisition of subsidiary,  --   --   (4,942)
Cash acquired in reverse purchase  --   --   13 
Net cash used in investing activities  --   4   (5,465)
Cash Flows from Financing Activities            
Proceeds from issuance of common stock  --   --   11,630 
Borrowing from shareholders  --   --   972 
Increase in notes payable and other short-term advances  1,698   510   44,650 
Decrease in notes payable and other short-term advances  --   --   (1,490)
Loan fees  --       (130)
Net cash used in financing activities  1,698   510   55,632 
             
Effect on foreign exchange rate on cash  (2)  (5)  662 
Net change in cash  237   (1,086)  619 
             
Cash, beginning of period  382   1,811   -- 
Cash, end of period E619  E 725   619 
Supplemental Noncash Financing Activity: Issuance of shares on conversion of notes payable
 E1,165   E --      
  
FOR THE
NINE
MONTHS ENDED SEPTEMBER 30, 2011
  
FOR THE
NINE
MONTHS ENDED SEPTEMBER 30, 2010
  
TOTAL ACCUMULATED
DURING THE
DEVELOPMENT STAGE
AS OF SEPTEMBER 30, 2011
 
Cash Flow from Operating Activities         
Net loss E(9,317) E(8,660) E(62,835)
Adjustments to reconcile net loss to net cash used in operating activities            
Change in the fair value of acquisition-related contingent consideration  2,583   825   2,245 
Depreciation  43   91   770 
Amortization of intangibles  144   145   481 
Impairment of license contract  2,213   --   2,213 
Goodwill impairment  --   --   209 
Fees paid in warrants  --   --   223 
Gain on sales of equipment  (1)  --   (69)
Gain on extinguishment of debt  --   --   (774)
Services and fee paid in common stock  --   179   5,403 
Stock compensation expense – options  70   206   308 
Amortization of debt discount  600   300   1,410 
Induced conversion cost  --   807   807 
Warrant modification cost  --   484   484 
Changes in operating assets and liabilities,            
Receivables  60   (50)  30 
Accounts payable  (231)  (110)  1,690 
Taxes and social costs payable  (24)  (25)  2 
Other  (28)  5   (13)
Net cash used in operating activities  (3,888)  (5,803)  (47,416)
Cash Flows from Investing Activities            
Patents and other  --   --   (393)
Proceeds from sale of equipment  --   --   137 
Purchase of property and equipment  --   (17)  (251)
Acquisition of subsidiary,net of cash acquired of E58  --   --   (4,942)
Cash acquired in reverse purchase  --   --   13 
Net cash provided by (used in) investing activities  --   (17)  (5,436)
Cash Flows from Financing Activities            
Proceeds from issuance of common stock  --   --   11,630 
Borrowing from shareholders  --   --   972 
Increase in notes payable and other short-term advances
  2,691   5,006   41,823 
Decrease in notes payable and other short-term advances
  --   --   (1,490)
Loan fees  --   --   (130)
Net cash provided by financing activities  2,691   5,006   52,805 
             
Effect on foreign exchange rate on cash  25   (26)  686 
             
Net change in cash  (1,172)  (840)  639 
             
Cash, beginning of period  1,811   2,959   -- 
             
Cash, end of period E 639  E2,119  E639 
Supplemental Noncash Financing Activity:            
Conversion of note payable and accrued interest to common stock E 2,319  E --     
 
The accompanying notes are an integral part of these financial statements.
 
 
 
 
 
MYMETICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011MARCH 31, 2012
(UNAUDITED)
 
Note 1. The Company and Summary of Significant Accounting Policies
 
BASIS OF PRESENTATION

The amounts in the notes are shown in thousands of EURO rounded to the nearest thousand except for share and per share amounts.

The accompanying interim period consolidated financial statements of Mymetics Corporation (the "Company") set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2010.2011.

The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending September 30, 2011March 31, 2012 were of a normal and recurring nature.

The Company was created for the purpose of engaging in vaccine research and development. Its main research efforts have been concentrated in the prevention and treatment of the AIDS virus untiland malaria. The Company has established a network which enables it acquired an ongoing malaria vaccine project from one of its close scientific partners.to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. On April 1, 2009 the Company successfully closed its acquisition of Bestewil Holding BV and Mymetics BV (previously Virosome Biologicals BV) and, as a result, has further increased the pipeline of vaccines under development to include (i) Respiratory Syncytial Virus (RSV) which is at the end of pre-clinical stage (ii) Herpes Simplex which is at the pre-clinical stage, and (iii)intra-nasal influenza which has finished a clinical trial Phase I  in collaboration with Solvay Pharmaceuticals (now Abbott Laboratories). Due to strategic changes and reprioritization efforts at Abbott Laboratories, Mymetics has regained the rights to its intra-nasal influenza vaccine product. Mymetics will now evaluate new strategic partners for this intra-nasal influenza vaccine. The Company has established a network of partners and sub-contractors to further develop its vaccines, including education centers, research centers, pharmaceutical laboratories and biotechnology companies.I.

These financial statements have been prepared treating the Company as a development stage company. As of September 30, 2011,March 31, 2012, the Company is in the initial stages of clinical testing and a commercially viable product is not expected for several more years. As such, the Company has not generated significant revenues. For the purpose of these financial statements, the development stage started May 2, 1990.

These financial statements have also been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in a deficit accumulated during the development stage of E62,835E66,524 at September 30, 2011.March 31, 2012. Deficits in operating cash flows since inception have been financed through debt and equity funding sources. In order to remain a going concern and continue the Company's research and development activities, management intends to seek additional funding. Further, the Company’s current liabilities exceed its current assets by E6,290 as of March 31, 2012, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts.
 
 
 
 
 
PRINCIPLES OF CONSOLIDATION
 
The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intra-entityintercompany accounts and transactions have been eliminated.

FOREIGN CURRENCY TRANSLATION

The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.

CASH

Cash deposits are occasionally in excess of insured amounts. No interest was paid for the three or nine months ended September 30,March 31, 2012 and 2011, and 2010, respectively.

REVENUE RECOGNITION

Revenue related to the sale of products is recognized when all of the following conditions are met: persuasive evidence of an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured.
 
Grant revenue is recognized when the associated costs are incurred.

RECEIVABLES

Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. Based on this review procedure, management has determined that the allowance at September 30, 2011March 31, 2012 and at December 31, 20102011 are sufficient. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.

PROPERTY AND EQUIPMENT

Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.

LICENSE CONTRACT

The license contract was acquired as part of the acquisition of Bestewil. It was amortized over 14 years on a straight-line basis until September 2011. The Company has regained access tolicense agreement with Solvay was reclaimed by Mymetics in October 2011, therefore the rightsremaining value of the intra-nasal vaccine related to the license contract. As the Company will no longer receive license fees related to the license contract, the license contract has been fully impaired and written off.was written-off.

IN-PROCESS RESEARCH AND DEVELOPMENT

In-process research and development (referred to as IPR&D) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&D assets acquired in a business combination are capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinite-lived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired.
 
 
 
 
The Company has contracted with an accounting firm to carry out the impairment testing as of April 1, 2011 of its IPR&D assets related to RSV and HSV. No impairment loss was  necessary based on the testing performed.

IMPAIRMENT OF LONG-LIVED ASSETS

Long-lived assets, which include property and equipment, and the license contract, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income in the period that the impairment occurs. As described above, the license contract has been fully impaired and written off.off in 2011.

GOODWILL

Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis as of April 1st of each year or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment model prescribes a two-step method for determining goodwill impairment. In the first step, the Company determines the fair value of its reporting unit using an enterprise value analysis. If the net book value of its reporting unit exceeds the fair value, then the second step of the impairment test is performed which requires allocation of the Company’s reporting unit’s fair value to all of its assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations with any residual fair value being allocated to goodwill. An impairment charge will be recognized only when the implied fair value of the reporting unit’s goodwill is less than its carrying amount.

The Company has contracted with an accounting firm to carry out theconducted its impairment testing as of April 1, 2011 of its goodwill recognized in connection to the acquisition of Bestewil. In conclusion of this impairment testing, the carrying amount of the reporting unit was lower than the estimated fair value of the reporting unit. As the fair value of the reporting unit is higher than the carrying amount, Step 2 of the goodwill impairment test did not need to be completed.completed and no impairment has been recognized in 2011.

CONTINGENT CONSIDERATION

The Company accounts for contingent consideration in a purchase business combination in accordance with applicable guidance provided within the business combination rules. As part of the consideration for the Bestewil acquisition, the Company is contractually obligated to pay additional purchase price consideration upon achievement of certain commercial milestones. Therefore, the Company is required to update the assumptions at each reporting period, based on new developments, and record such amounts at fair value until such consideration is satisfied. Because of incertainties inherent in estimates, it is at least reasonably possible that a change in the estimate of the contingent consideration will occur in the near term.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred.

 
TAXES ON INCOME

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.
 

The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.

The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at September 30, 2011March 31, 2012 or at December 31, 2010.2011.  The Company’s United States tax returns are open to audit for the years ended December 31, 20072008 to 2010.2011. The returns for the Luxembourg subsidiary LUXEMBOURG 6543 S.A., are open to audit for the year ended December 31, 2010.2011. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the years ended December 31, 20072008 to 2010.2011. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, 2010.2011.

EARNINGS PER SHARE

Basic earnings per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding in the common  period. The weighted average number of shares was 227,058,154286,834,649 and 201,657,505213,963,166 for the three months ended September 30,March 31, 2012 and 2011, and 2010, respectively. The weighted average number of shares was 218,376,129 and 198,047,647 for the nine months ended September 30, 2011 and 2010, respectively. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. Options, warrants and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred. For the ninethree months ended September 30,March 31, 2012, the total potential number of shares issuable of 145,545,352 includes 89,634,402 potential issuable shares related to  convertible loans, 51,218,450 potential issuable shares related to warrants, and 4,692,500 potential issuable shares related to outstanding not expired options granted to employees. For the three months ended March 31, 2011, the total potential number of shares issuable of 173,611,678140,082,223 includes 117,650,72884,121,273 potential issuable shares related to  convertible loans, 51,218,450 potential issuable shares related to warrants, and 4,742,500 potential issuable shares related to outstanding options granted to employees. For the nine months ended September 30, 2010, the total potential number of shares issuable of 134,796,337 includes 81,285,387 potential issuable shares related to convertible loans, 51,218,450 potential issuable shares related to warrants, and 2,292,500 potential issuable shares related to outstanding options granted to employees.

PREFERRED STOCK

The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at September 30, 2011.March 31, 2012.

STOCK-BASED COMPENSATION

Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.

The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. 1,750,000No shares were issued to individuals as fee for services rendered in the ninethree months ended September 30, 2010.March 31, 2012 or in the three months ended March 31, 2011.

Mymetics didn’t grant any stock options to employees in 2011 or during the three month period ending March 31, 2012.
 
 
 
 
 
No options were issued in the three and nine months ended September 30, 2011. During the nine month period ending September 30, 2010, the Board of Directors of Mymetics awarded 4,350,000 incentive stock options to the employees and officers of the Company. Incentive stock options were awarded on June 30, 2010, for a total of 3,350,000 shares with an exercise price of USD 0.14 per share, of which 1,850,000 vested immediately and 1,500,000 vest in equal quantities over the next three years. As part of the employment contract with the CFO of Mymetics, 1,000,000 employee incentive stock options were issued during the three months ended September 2010 with an exercise price of USD 0.19 per share, of which 250,000 vested immediately and 750,000 vest in equal quantities over the next three years.ESTIMATES

ESTIMATES
The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

FAIR VALUE MEASUREMENTS

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

Level  1-Quoted prices in active markets for identical assets or liabilities.
Level  2-Inputs other than Level 1 that are observable, either directly or indirectly,orindirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level  3-Unobservable inputs that are supported by little or no market activity andactivityand that are significant to the fair value of the assets or liabilities.

FAIR VALUES OF FINANCIAL INSTRUMENTS

The Company generally has the following financial instruments: cash, employee receivables, other receivables, accounts payable, taxes and social costs payable, acquisition-related contingent consideration and notes payable. The carrying value of cash, employee receivables, other receivables, accounts payable, and taxes and social costs payable approximateapproximates their fair value based on the short-term nature of these financial instruments. The carrying value of acquisition-related contingent consideration is equal to fair value since this liability is required to be reported at fair value. Due to the unique nature of the notes payable, managementManagement believes it is not practicable to estimate the fair value of the notes payable due to the unique nature of these instruments.

CONCENTRATIONS

The Company enters into scientific collaboration agreements with selected partners such as Pevion Biotech Ltd., a Swiss company that granted Mymetics exclusive licenses to use their virosome vaccine delivery technology in conjunction with the Company’s AIDS and malaria preventive vaccines under development. Under this agreement, Pevion Biotech is committed to supply the actual Virosomes and perform their integration with the Company’s antigens, which requires proprietary know-how, at Pevion’s premises. The agreement includes specific mechanisms to mitigate the risk of losing a key component of Mymetics’ vaccines should Pevion become unable to meet its commitment.

RELATED PARTY TRANSACTIONS

The Company's general counsel is a member of the Board of Directors.  The Company incurred professional fees to the counsel's law firm duringtotaling E20 and E25 for the period of three months ending March 31, 2012 and nine months ended September 30, 2011, totaling E21 and E67, respectively. The professional fees incurred by the Company to the counsel's law firm during the three and nine months ended September 30, 2010, totaled E28 and E101, respectively.

COMMITMENTS

As per an agreement signed on December 22, 2008, PX Therapeutics has granted the license rights of the general know-how of Gp41 manufacturing technology to Mymetics for five years. During this period, the Company pays to PX Therapeutics an annual fee of E200 until the expiration date of December 23, 2013. The thirdfourth milestone payment of E200 is due on December 23, 2011.2012.

NEW ACCOUNTING PRONOUNCEMENTS

No new accounting pronouncements are expected to have a material impact on the Company’s consolidated financial statements.
 
Note 2. Intangible Assets

Intangible assets consisted of the followingin process research and development at September 30, 2011March 31, 2012 and December 31, 2010:
  
September
30, 2011
  
December
31, 2010
 
       
Indefinite-lived intangibles:      
In process research and development E2,266  E2,266 
         
Definite-lived intangibles:        
License contract E--  E2,694 
Less accumulated amortization  --   (337)
         
   --   2,357 
         
Other intangibles, net E2,266  E4,623 
2011.

During the nine monthsyear ended September 30,December 31, 2011, thea license contract has beenintangible asset was  returned to Mymetics and therefore it has been fully impaired and written off.

Amortization of intangibles amounting to E144 and E145E48 has been recorded during the ninethree months ended September 30,March 31, 2011 and 2010, respectively.none for the respective period in 2012.
 
Note 3. Acquisition-Related Contingent Consideration

On April 1, 2009, Mymetics and Norwood Immunology Limited (“NIL”) closed the acquisition of Bestewil Holding B.V. (“Bestewil”) from its parent, NIL, under a Share Purchase Agreement pursuant to which Mymetics agreed to purchase all issued and outstanding shares of capital stock (the “Bestewil Shares”) of Bestewil from its parent, NIL, and all issued and outstanding shares of capital stock of Virosome Biologicals B.V. which were held by Bestewil.
 
The contingent consideration to be paid under the Share Purchase Agreement includes:

·A payment of up to E3,000 in cash should a third party commence a Phase III clinical trial by April 1, 2013 for Mymetics’ Intranasal Influenza Vaccine licensed from Bestewil;

·
·
A payment of 50% of Mymetics’ net royalties received from a Respiratory  Syncytial Virus license (RSV license), payable in cash, maximum amount unlimited; and

·
·
A payment in cash, maximum amount unlimited, of 25% of any net amounts received by Mymetics from a third party Herpes Simplex Virus license (HSV license) based upon Bestewil intellectual property.

The fair value of the contractual obligations to pay the contingent consideration is determined based on a risk-adjusted, discounted cash flow approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The resultant cash flows are discounted using a discount rate of 25%13.9%, which the Company believes is appropriate and is representative of a market participant assumption.
 
The fair value of the contingent consideration due to NIL according to the achievement of certain milestones and royalties on the vaccines RSV, HSV and Influenza is estimated at E5,795E6,547 as of September 30, 2011.March 31, 2012. Due to the termination of the licence contract with Abbott for the influenza patent in October 2011, the portion of the contingent consideration liability related to influenza is nil as of September 30, 2011.March 31, 2012.
 
The following table presents changes to the Company’s acquisition-related contingent consideration for the period ending September 30, 2011:March 31, 2012:
 
  Fair Value Measurements Using Significant 
   Unobservable Inputs(Level 3) 
  Acquisition-related Contingent Consideration 
  
As recorded on
December 
31, 2010
  
  Measurement
Adjustment
  
As adjusted on
September 30, 2011		 
          
Royalties for RSV E329  E2,887  E3,216 
Royalties for HSV E1,923  E656  E2,579 
Royalties for Influenza Vaccines E960  E(960)  E-- 
             
Total Contingent Consideration  3,212  E2,583  E5,795 
  Fair Value Measurements Using Significant 
  Unobservable Inputs(Level 3) 
  Acquisition-related Contingent Consideration 
  As recorded on  Measurement  As adjusted on 
  December 31,2011  Adjustment  March 31, 2012 
          
Royalties for RSV E 3,216  E 236  E 3,452 
Royalties for HSV E 2,537  E 558  E 3,096 
Royalties for Influenza Vaccines E --  E --  E -- 
             
Total Contingent Consideration E 5,753  E 794  E 6,547 

During the ninethree month period ending September 30, 2011,March 31, 2012, the fair value of the acquisition-related contingent consideration increased by E2,583.E794 compared to the period ending December 31, 2011. The increase is due to a decrease in time as the milestones become closer.

The fair value recorded as of DecemberMarch 31, 20102012 was determined based on a projection period ending in 2023,2030 which corresponds to the lifetime of the underlying patents. This projection period has been extended to 2030 based onpatents and management’s revised assessment of the Company’s ability to generate new patents from its research, in the fair value calculation performed as of June 30, 2011 and September 30, 2011. This resulted in an adjustment of approximately E1,800 to the fair value calculation for the nine months ended September 30, 2011.research. The RSV vaccine wasis planned to be out-licensed after the pre-clinical phase with potential royalties of 2%. As of the date of this report, no out-licensing agreement has been made. Management’s new plan is to bring the RSV vaccine through a Phase I and II, which adds considerable value and changes expected royalties to 10% and therefore increases the liability due to NIL. This change had an additional impact of approximately E1,200 in the fair value calculation for the nine months ended September 30, 2011. Additionally, theII. The contingent consideration related to the intra-nasal influenza vaccine has been reduced to zero, as it is very unlikely that the Phase III clinical trial will start before April 1, 2013, now that the Company has regained the rights to the influenza vaccine technology.
 
Note 4. Debt Financing

To date, high net worth investors in Switzerland have purchased restricted common shares at prices which are at a premium to the market price of Mymetics shares, and have introduced management to other high net worth individuals who have a similar interest in the Company’s science and mission.
In addition to purchasing shares, certainCertain principal shareholders have granted the Company secured convertible notes (in accordance with the Uniform Commercial Code in the State of Delaware), and short term convertible notes, which have a total carrying value of E28,260E28,700 including interest due to date. Interest incurred on these notes since inception has been added to the principal amounts.

On August 5,February 10, 2012, the expired loan from Round Enterprises dated December 9, 2010, with a principal balance of E1,100 and maturity date December 16, 2011 41,542,722 shares were issued, triggered by a convertible loan maturing on July 31, 2011.has been agreed to be converted into 19,301,474 Mymetics common shares. The convertible note had an outstanding principal amount and accrued interest balancehave been converted into shares using an exchange rate of E2,319 at$1.3260 per Euro and a conversion price of $0.08 per share.

On February 14, 2012, an amendment was made to the maturity date of the $1,200 and the E400 convertible notes of Round Enterprises dated August 4, 2011 and November 8, 2011, respectively. On the same date the maturity date was also amended for the convertible notes of Eardley Holding of $300 and E100, dated August 4, 2011 and November 8, 2011, respectively. The new maturity date for these four loans has been amended to June 30, 2012.

On February 17, 2012, two new convertible loans from the Company’s main shareholders have been contracted for a total of E1,200 bearing an interest rate of 10%.The maturity date is June 30, 2012. The conversion date.price is determined by reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than $20,000.
 
The details of the convertible notes, loans and contingent liabilities are as follows at September 30, 2011:March 31, 2012:

              Fixed 
              EUR/USD 
           Conversion  Rate for 
  1st-Issue Principal  
Duration
 
Interest
 Price  Conversion 
Lender Date Amount  (Note) Rate (stated)  Price 
                
Norwood Secured Loan 04/03/2009 E 2,500   (5)5% pa $US 0.50   1.2812 
Round Enterprises Ltd. 08/04/2011 E 899   (7)10% pa None(9)   N/A 
Eardley Holding A.G. 08/04/2011 E 225   (7)10% pa None(9)   N/A 
Round Enterprises Ltd. 11/08/2011 E 400   (8)10% pa None(9)   N/A 
Eardley Holding A.G. 11/08/2011 E 100   (8)10% pa None(9)   N/A 
Round Enterprises Ltd. 02/17/2012 E 1,000   (8)10% pa None(9)   N/A 
Eardley Holding A.G. 02/17/2012 E 200   (8)10% pa None(9)   N/A 
    E 5,324              
Total Short Term Principal Amounts   E 486              
Accrued Interest                   
Total Short Term Notes                   
Payable to Related Parties   E 5,810              
 
             Fixed 
             EUR/USD 
      Dura- Inter- Conversion  Rate for 
 1st-Issue Principal  tion est Price  Conversion 
Lender Date Amount  (Note) Rate (stated)  Price 
                
Norwood Secured Loan 04/03/2009 E 2,500   (5) 5% pa  $US 0.50   1 
Round Enterprises Ltd. 09/30/2010 E 1,100   (7) 5% pa  None   N/A 
Round Enterprises Ltd. 12/17/2010 E 1,100   (8) 5% pa  None   N/A 
Round Enterprises Ltd. 08/04/2011 E 889   (9) 10% pa  None(10)   N/A 
Eardley Holding A.G. 08/04/2011 E 222   (9) 10% pa  None(10)   N/A 
                    
Total Short Term Principal Amounts   E 5,811               
Accrued Interest   E 428               
                    
Total Short Term Notes                    
Payable to Related Parties   E 6,239               
                    
Eardley Holding A.G. (1) 06/23/2006 E140   (2) 10% pa  $US 0.10   N/A  06/23/2006 E 142   (2)10% pa $US 0.10   N/A 
Anglo Irish Bank S.A. (3) 10/21/2007 E500   (2) 10% pa  $US 0.50   1  10/21/2007 E 500   (2)10% pa $US 0.50   1.409 
Round Enterprises Ltd. 12/10/2007 E 1,500   (2) 10% pa  $US 0.50   1  12/10/2007 E 1,500   (2)10% pa $US 0.50   1.4429 
Round Enterprises Ltd. 01/22/2008 E1,500   (2) 10% pa  $US 0.50   1  01/22/2008 E 1,500   (2)10% pa $US 0.50   1.4629 
Round Enterprises Ltd. 04/25/2008 E 2,000   (2) 10% pa  $US 0.50   2  04/25/2008 E 2,000   (2)10% pa $US 0.50   1.5889 
Round Enterprises Ltd. 06/30/2008 E 1,500   (2) 10% pa  $US 0.50   2  06/30/2008 E 1,500   (2)10% pa $US 0.50   1.538 
Round Enterprises Ltd. 11/18/2008 E 1,200   (2) 10% pa  $US 0.50   1  11/18/2008 E 1,200   (2)10% pa $US 0.50   1.265 
Round Enterprises Ltd. 02/09/2009 E 1,500   (2) 10% pa  $US 0.50   1  02/9/2009 E 1,500   (2)10% pa $US 0.50   1.294 
Round Enterprises Ltd. 06/15/2009 E 5,500   (2,4) 10% pa  $US 0.80   1  06/15/2009 E 5,500   (2,4)10% pa $US 0.80   1.4045 
Eardley Holding A.G. 06/15/2009 E 100   (2,4) 10% pa  $US 0.80   1  06/15/2009 E 100   (2,4)10% pa $US 0.80   1.43 
Von Meyenburg 08/03/2009 E 200   (2) 10% pa  $US 0.80   1  08/03/2009 E 200   (2)10% pa $US 0.80   1.44 
Round Enterprises Ltd. 10/13/2009 E 2,000   (2) 5% pa  $US 0.25   1  10/13/2009 E 2,000   (2)5% pa $US 0.25   1.4854 
Round Enterprises Ltd. 12/18/2009 E 2,200   (2) 5% pa  $US 0.25   1  12/18/2009 E 2,200   (2)5% pa $US 0.25   1.4338 
 04/03/2009                  
Total Long Term Principal Amounts 09/30/2010 E 19,840                  E19,842              
Accrued Interest 12/17/2010 E 4,993                  E 5,923              
 08/04/2011                  
Total Long Term Convertible Notes to Related Parties 08/04/2011 E 24,833                  E25,765               
                    
Total Convertible Notes to Related Parties   E 31,072                  E 31,575              
                    
Norwood Contingent Liability   E 5,795   (6)              E 6,547   (6)          
                    
TOTAL LOANS, NOTES, AND CONTINGENT LIABILITY   E36,867               
TOTAL LOANS, NOTES,AND CONTINGENT LIABILITY   E 38,122              
 
(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190,000.
$190.

(2) The earlier of: (i) the date that the Company has sufficient revenues to repay, or (ii) upon an event of default. The loan is secured against IP assets of Mymetics Corporation.

(3) Renamed Hyposwiss Private Bank Genève S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV.

(5) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company issued to Norwood Immunology Limited (“NIL”) a convertible redeemable note (the “Note”) in the principal amount of E2,500 with a maturity date of April 1st, 2012 and bearing interest at 5% per annum. The note is secured against 1/3rd of Bestewil common stock. Mymetics has subsequently renegotiated the loan with NIL (see note 6).

(6) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company is committed to make further payments to NIL in the event that certain stated milestones for the development of vaccines are achieved. These have been considered on a risk probability basis.

(7) The loan has matured on September 30, 2011. A subsequent agreement has been made to convertloans expire the loan, including the accrued interest as of October 31, 2011, into 20,511,451 shares at a conversion price of $0.08 per share.

(8) The earlier of (i) December 16, 2011 or (ii) upon an event of default.

(9) The earlier of (i) January 31,June 30, 2012 or (ii) upon an event of default. The face valuevalues of boththe loans isare stated in U.S. dollars at $1,500,000 total.
$1,200 and $300, respectively.

(8) The loans expire the earlier of (i) June 30, 2012 or (ii) upon an event of default.
(10) Theconversion
(9) The conversion feature is contingent on an investment in the Company of not less than $20,000,000.$20,000. The conversion price is determined by reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with such an investment.

Required future payments on long-term debt are as follows as of March 31, 2012:

2012 E 5,810 
Contingent liability to Norwood (milestones and royalties)  6,547 
Contingent on ability to repay  25,765 
  E38,122 
 
Note 5. Equity Financing

The Company relied on its existing high net worth shareholders until now. The Company is in discussions with certain potential investors and lenders to meet the Company’s expenses during the next ninesix months and beyond.
 
Note 6. Subsequent Events

During October 2011,On April 19, 2012, Mymetics has agreed with Norwood Immunology Ltd. (NIL) to amend the Boardterms and conditons of Mymetics and Round Enterprises agreed to convert the E2,500 loan of E1.1 million includingthat expired on April 1, 2012. The amended agreement resulted in the payment E402 covering all the accrued interest that has matureddue to NIL on April 20, 2012 and a delay of the repayment of the E2,500 loan until September 30, 2012, with a 5% interest per annum starting from April 20, 2012. The repayment of the loan will be half in shares and half in cash and is contingent on an investment in the Company of not less than $20,000 by new investors. The conversion price is determined by reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with such an investment. In the case Mymetics is not able to close the investment of not less than $20,000 before or on September 30, 2011, into 20,511,451 shares at2012, the terms of the loan will revert to the original terms and the loan and accrued interest becomes immediately payable as the loan would be in default.

On April 19, 2012, Round Enterprises Ltd and Eardley Holding AG each provided a convertible loan of E322 and E80, respectively, with a 10% interest per annum and a maturity date of September 30, 2012. The conversion price of $0.08is determined by reducing by 10% the price per share.
During October 2011, the Board of Mymetics appointed Martine Reindle, oneshare of the foundersCompany’s common stock paid by the investors in connection with an investment in the Company of Mymetics,not less than $20,000.

On May 4, 2012, Round Enterprises Ltd. and Eardley Holding AG each agreed to provide a convertible loan of E480 and E120, respectively, with a 10% interest per annum and a maturity date of July 31, 2012. The conversion price is determined by reducing by 10% the Boardprice per share of Directors to fill a current vacancy on the Board.Company’s common stock paid by the investors in connection with an investment in the Company of not less than $20,000.
 
 
 
 
 
ITEM  2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

The following discussion and analysis of the results of operations and financial condition of Mymetics Corporation for the periods ended September 30,March 31, 2012 and 2011 and 2010 should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 20102011 and related notes and the description of the Company's business and properties included elsewhere herein.

This report contains forward-looking statements that involve risks and uncertainties. The statements contained in this report are not purely historical, but are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Words such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue", "probably" or similar words are intended to identify forward looking statements, although not all forward looking statements contain these words.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We are under no duty to update any of the forward-looking statements after the date hereof to conform such statements to actual results or to changes in our expectations.

Readers are urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation disclosures made under the captions "Management Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors,""Consolidated "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements" included in our annual report on Form 10-K for the year ended December 31, 20102011 and, to the extent included therein, our quarterly reports on Form 10-Q filed during fiscal year 2010.2011.

THREE MONTHS ENDED SEPTEMBER 30,MARCH 31, 2012 AND 2011 AND 2010

Revenue was E110nil for the three months ended September 30,March 31, 2012, as the license agreement with Solvay was terminated in October 2011. Revenue in the three months ending March 31, 2011 of which E75 relates to licensing agreements.was E39. This revenue has been earned by Mymetics BV (the acquired company “Bestewil Holding/Virosome Biological”).

Costs and expenses decreasedincreased to E3,148E2,467 for the three months ended September 30, 2011March 31, 2012 from E4,590 (-31.4%E1,735 (42.2%) for the three months ended September 30, 2010,March 31, 2011, mainly due to a change in the acquisition-related contingent consideration and significant R&Dincrease in research and G&A decreases, offset by E2,213 of license contract impairment.development expenses.

Research and development expenses decreasedincreased to E173E786 in the current period from E978 (-82.3%E440 (78.6%) in the comparative period of 2010.2011. The decreaseincrease of R&D was mainlydue to the invoice received from INSERM related to efforts of the Company to reduce expenses until it secures additional equity financing to allow it to enter into the clinical trials for its HIVa E400 milestone payment. This payment is under negotiation between Mymetics and RSV vaccines.INSERM.
 
General and administrative expenses decreased to E522E368 in the three months ended September 30, 2011March 31, 2012 from E1,273 (-59.0%E416 (-11.5%) in the comparative period of 2010.2011. This was mainly due to a reduction in payroll legal and investor relation costs incurred in the period ended September 30, 2010 related to the issuance of third party contracts and start up costs for a fund raising program, respectively.March 31, 2012.

 
 
 
 
A reduction in the conversion price of shareholder debt resulted in an expense of E807 recorded during the three months ended September 30, 2010.
Interest expense decreased to E535E529 for the three months ended September 30, 2011March 31, 2012 from E784E819 for the three months ended September 30, 2010.March 31, 2011. This was mainly related to the conversion of a short term notenotes payable into shares of common stock in August 20112012 and E300at the end of amortization of the debt discount related to the warrant that was issued in conjunction with a note payable on July 1, 2010.2011.

A reassessment of fair value required an E432 decreaseE794 increase in the acquisition-related contingent consideration liability and fair value during the three months ended September 30, 2011March 31, 2012 mainly due to the termination offact that the license agreement with Abbott of our influenza vaccine that triggered a write off of the influenza license contract and associated acquisition-related contingent consideration liability.time to market is getting closer.

The Company reported a net loss of E3,038,E2,467, or E0.01 per share, for the three months ended September 30, 2011,March 31, 2012, compared to a net loss of E4,551,E1,700, or E0.02E0.01 per share, for the three months ended September 30, 2010.

NINE MONTHS ENDED SEPTEMBER 30, 2011 AND 2010
Revenue was E187 and E116 for the nine months ended September 30, 2011 and 2010, respectively, related mainly to licensing agreements. This revenue has been earned by Mymetics BV (the acquired company “Bestewil Holding/Virosome Biological”).
Costs and expenses increased to E9,504 for the nine months ended September 30, 2011 from E8,776 (8.3%) for the nine months ended September 30, 2010, mainly due to a change in the acquisition-related contingent consideration and significant R&D and G&A decreases, offset by E2,213 of license contract impairment.
Research and development expenses decreased to E922 in the current period from E2,239 (-58.8%) in the comparative period of 2010. The decrease of R&D was mainly related to efforts of the Company to reduce expenses until it secures additional equity financing to allow it to enter into the clinical trials for its HIV and RSV vaccines.
General and administrative expenses decreased to E1,344 in the nine months ended September 30, 2011 from E2,646 (-49.2%) in the comparative period of 2010. This was mainly due to an increase in, payroll, legal and investor relation costs incurred in the period ended September 30, 2010 related to the issuance of 3rd party contracts and start up costs for a fund raising program, respectively.
A reduction in the conversion price of shareholder debt resulted in a E807 expense recorded during the nine months ended September 30, 2010. No such expense was incurred during the nine months ended September 30,March 31, 2011.
Interest expense increased to E2,183 for the nine months ended September 30, 2011 from E2,006 for the nine months ended September 30, 2010. This was mainly related to the conversion of a short term note payable into shares of common stock in August 2011 and E300 more of amortization of the debt discount related to the warrant that was issued in conjunction with a note payable on July 1, 2010.
A reassessment of fair value required an increase of E2,583 in the fair value of  acquisition-related contingent consideration during the nine months ended September 30, 2011. This was mainly due to higher expected future milestone payments related to the RSV vaccine. Further, the timelines for possible out-licensing upfront and milestone payments for the RSV and HSV vaccine candidates have been moved out to reflect the Company’s strategy to out-license after a successful Phase II and start of a Phase III. This was offset by the termination of the influenza license agreement with Abbott.
The Company reported a net loss of E9,317, or E0.04 per share, for the nine months ended September 30, 2011, compared to a net loss of E8,660, or E0.04 per share, for the nine months ended September 30, 2010.
 
LIQUIDITY AND CAPITAL RESOURCES

We had cash of E639E619 at September 30, 2011March 31, 2012 compared to E1,811E382 at December 31, 2010.2011.

We have not generated any material revenues since we commenced our vaccine research and development business in 2001, and we do not anticipate generating any material revenues on a sustained basis unless and until a licensing agreement or other commercial arrangement is entered into with respect to our technology.

As of September 30, 2011,March 31, 2012, we had an accumulated deficit of approximately E63E67 million, and we incurred losses of E9,317E2,467 in the ninethree month period ending on that date. These losses are principally associated with the research and development of our vaccine technologies and the change in acquisition-related contingent consideration and impairment of the license contract.consideration.  We expect to continue to incur expenses in the future for research, development and activities related to the future licensing of our technologies.

Net cash used in operating activities was (E3,888)(E1,459) for the ninethree month period ended September 30, 2011,March 31, 2012, compared to (E5,803)(E1,595) for the period ended September 30, 2010.March 31, 2011.

Investing activities useddidn’t provide any cash of (E17) during the ninethree months ended September 30, 2010.March 31, 2012, compared to E4 during the three months ended March 31, 2011.

Financing activities provided cash of E2,691E1,698 and E5,006E510 for the ninethree months ended September 30,March 31, 2012 and 2011, and 2010, respectively.

Salaries and related payroll costs represent gross salaries for 3 executives, our three directorsCSO of Mymetics BV and fourfive employees. Under Executive Employment Agreements with our CEO, CFO and CSO, and a consulting contract with our CEO, we pay our executive officers a combined amount of E57E44 per month. This is exclusive of our contracts for the consulting services of Professor Marc Girard. The consulting contract
On January 30, 2012, Jacques-François Martin resigned as President and CEO of Mymetics no later than effective May 1, 2012 but he remained as Chairman of the Board. On March 23, 2012 we announced that in connection with Mr.our financing efforts and decision to pursue new strategic alternatives, including moving our headquarters to the United States, we appointed Dr. Christopher S. Henney to be Chairman of our Board of Directors and Grant Pickering to be President and CEO and a member of our Board of Directors. We also added Ulrich Burkhard, Managing Partner and Director of the Marcuard Family Office, as a director. Concurrent with the appointment of these three individuals to these Board and executive positions, Jacques-François Martin resigned as Chairman of our Board of Directors and Sylvain Fleury, Christian Rochet who was employed by the Companyand Martine Reindle resigned as Senior Advisor to the President, terminated asmembers of April 30, 2011.Board of Directors.

Mr. Jacques-François MartinGrant Pickering is our President and Chief Executive Officer, and Mr. Ronald Kempers is Chief Financial Officer and Chief Operating Officer and Mr. Sylvain Fleury is Chief Scientific Officer. In addition, our Swiss subsidiary, Mymetics S.A., has on its payroll two assistants to our CFOemployees: Director of Finance and CSO, respectively.a Director of R&D. Mymetics BV has one full time director (CSO)a Chief Scientific Officer, Mr. Toon Stegmann, plus twothree full-time assistants. As of September 30, 2011,March 31, 2012, our Luxembourg affiliate had no employees.

The nine member Scientific Advisory Board (SAB) created in 2009, is composed of emminent intellectuals from around the world with expertise related to the Company’s products as follows:

Chairman of the Scientific Advisory Board - Dr. Stanley Plotkin, Emeritus Professor Wistar Institute, University of Pennsylvania, consultant to Sanofi Pasteur, developed the rubella vaccine in 1960s; worked extensively on the development and application of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus as well as senior roles at the Epidemic Intelligence Service, U.S. Public Health Service; Aventis Pasteur (medical and scientific director); and Sanofi Pasteur (executive advisor).

Vice Chairman of the Scientific Advisory Board - Dr. Marc Girard, has over 20 years of experience in the HIV-1 research field, past Director of the Mérieux Foundation and a consultant to the WHO and former Chairman of EuroVac (European Consortium for HIV vaccine).

●Dr. Ruth Ruprecht, Harvard University, Dana Farber Cancer Institute, Boston USA
●Dr. Ronald H. Gray, Johns Hopkins University, Baltimore, USA
●Dr. Malegapuru William Makgoba, University of KwaZulu-Natal, Durban, South Africa
●Dr. Souleymane Mboup, Cheikh Anta DIOP University, Dakar, Sénégal
●Dr. Juliana McElrath, University of Washington, Seattle, USA
●Dr. Odile Puijalon, Pasteur Institute, Paris, France
●Dr. Caetano Reis e Sousa, Cancer Research UK, London, UK

Monthly fixed and recurring expenses for "Property leases" of E11 represent the monthly lease and maintenance payments to unaffiliated third parties for our offices, of which E4 is related to our executive office located at Route de la Corniche 4, 1066 Epalinges in Switzerland (100 square meters), and E7 related to Bestewil Holding B.V. and its subsidiary Mymetics B.V operating from a similar biotechnology campus near Leiden in the Netherlands, where they occupy 100 square meters. The lease related to the office located at 14, rue de la Colombiere in Nyon (Switzerland) (100 square meters) has been cancelled as of end of February 2011.

Included in professional fees are legal fees paid to outside corporate counsel and audit and review fees paid to our independent accountants, and fees paid for investor relations.

Cumulative interest expense of E5,421E6,409 has been incurred on all of the Company’s outstanding notes and advances (see detailed table in Note 4 to the financial statements).

We intend to continue to incur additional expenditures during the next 12 months for additional research and development of our HIV, Respiratory Syncytial Virus and Herpes Simplex vaccines, while also further developing the R&D at Mymetics BV (Leiden) and Mymetics Corporation (Epalinges). Additional funding requirements during the next 12 months will arise as we continue to develop the pipeline of vaccines and move forward in our clinical trials. We expect that funding for the cost of any clinical trials will be available either from debt or equity financings, donors and/or potential pharmaceutical partners before we commence the human trials.

In the past we have financed our research and development activities primarily through debt and equity financings from various parties.

We anticipate our operations will require approximately E15 millionE6,000 until December 31, 2012. To allow the Company to achieve its business plan, we are engaged with several parties, including Gilford Securities, to raise US$40,000,00040,000 through a combination of equity and debt financing.   Under the terms of the letter of engagement with Gilford Securities dated February 4, 2010, we will (i) pay a cash fee of 8% of the purchase price of the Series A Preferred Stock sold by Gilford Securities, not including up to US$15,000,000 that we are allowed to sell to investors which are not introduced by Gilford Securities, (ii) register the shares of our common stock underlying the Series A Preferred Stock within three months of selling a minimum of US$40,000,000 of Series A Preferred Stock. The proposed Series A Preferred Stock is nonvoting, convertible into shares of our common stock at a price of US$.50 per share, preferred as to liquidation only and will not pay any dividend. We will continue to seek to raise the required capital from donors and/or potential partnerships with major international pharmaceutical and biotechnology firms. However, there can be no assurance that we will be able to raise additional capital on terms satisfactory to us, or at all, to finance our operations. In the event that we are not able to obtain such additional capital, we would be required to further restrict or even halt our operations.

RECENT FINANCING ACTIVITIES

During the three month period ending March 31, 2012, our principal source of funds has been shareholder loans.

On February 10, 2012, the expired loan from Round Enterprises dated December 9, 2010, with a principal balance of E1,100 and maturity date December 16, 2011 has been agreed to be converted into 19,301,474 Mymetics common shares. The principal amount and accrued interest have been converted into shares using an exchange rate of $1.3260 per Euro and a conversion price of $0.08 per share.

On February 14, 2012, an amendment was made to the maturity date of the $1,200 and the E400 convertible notes of Round Enterprises dated August 4, 2011 and November 8, 2011, respectively. On the same date the maturity date was also amended for the convertible notes of Eardley Holding of $300 and €100, dated August 4, 2011 and November 8, 2011, respectively. The new maturity date for these four loans has been amended to June 30, 2012.

On February 17, 2012, two convertible loans from the Company’s main shareholders have been contracted for a total of E1,200 bearing a interest rate of 10%.The maturity date is June 30, 2012. The conversion price is determined by reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than $20,000.

  On April 19, 2012, Norwood Immunology Ltd (NIL) agreed to an amendment to the E2,500 loan agreement. The amended agreement resulted in the payment E402 on April 20, 2012 covering all the accrued interest due to NIL and a delay of the repayment of the E2,500 loan until September 30, 2012, with a 5% interest per annum starting from April 20, 2012. The repayment of the loan will be half in shares and half in cash and is contingent on an investment in the Company of not less than $20,000 by new investors. The conversion price is determined by reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with such an investment. In the case Mymetics is not able to close the investment of not less than $20,000 from new investors before or on September 30, 2012, the loan and accrued interest becomes immediately payable.

On April 19, 2012, Round Enterprises Ltd. and Eardley Holding AG each provided a convertible loan of E322 and E80, respectively, with a 10% interest per annum and a maturity date of September 30, 2012. The conversion price is determined by reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than $20,000.

On May 4, 2012, Round Enterprises Ltd. and Eardley Holding AG each provided a convertible loan of E480 and E120, respectively, with a 10% interest per annum and a maturity date of July 31, 2012. The conversion price is determined by reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than $20,000.

We have filed or are in the process of filing several new grant applications with European as well as U.S. Institutions in relation to our HIV-1 and malaria vaccines.

We anticipate using our current funds and those we receive in the future both to meet our working capital needs and for funding the ongoing research costs associated with our gp41 testing. Provided we can obtain sufficient financing resources, we expect to continue the development for our HIV and RSV vaccine in 2012. In accordance with our past strategy, we intend to subcontract such work to "best of class" research teams unless institutions such as the US National Institutes of Health (NIH) decide to conduct such trials at their own expense, which they presently do.
We do not anticipate that our existing capital resources will be sufficient to fund our cash requirements through the next six months. We do not have enough cash presently on hand, based upon our current levels of expenditures and anticipated needs during this period, and we will need additional proceeds from additional equity investments such as private placements under Regulation D and Regulation S under the Securities Act of 1933. We do not know whether additional financing will be available on commercially acceptable terms when needed.

If management cannot raise funds on acceptable terms when needed, we may not be able to successfully commercialize our technologies, take advantage of future opportunities, or respond to unanticipated requirements. If unable to secure such additional financing when needed, we will have to curtail or suspend all or a portion of our business activities and could be required to cease operations entirely. Further, if new equity securities are issued, our shareholders may experience severe dilution of their ownership percentage.

The extent and timing of our future capital requirements will depend primarily upon the rate of our progress in the research and development of our technologies, our ability to enter into one or more licensing or partnership agreements with pharmaceutical companies, and the results of future clinical trials.

To date we have generated no material revenues from our business operations. We are unable to predict when or if we will be able to generate revenues from licensing our technology or the amounts expected from such activities. These revenue streams may be generated by us or in conjunction with collaborative partners or third party licensing arrangements, and may include provisions for one-time, lump sum payments in addition to ongoing royalty payments or other revenue sharing arrangements. However, we presently have no commitments for any such payments.
We anticipate using our current funds and those we receive in the future both to meet our working capital needs and for funding the ongoing research costs associated with our gp41 testing. Provided we can obtain sufficient financing resources, we expect to continue the development for our HIV and RSV vaccine in 2011. In accordance with our past strategy, we intend to subcontract such work to "best of class" research teams unless institutions such as the US National Institutes of Health (NIH) decide to conduct such trials at their own expense, which they presently do.
We do not anticipate that our existing capital resources will be sufficient to fund our cash requirements through the next twelve months. We do not have enough cash presently on hand, based upon our current levels of expenditures and anticipated needs during this period, and we will need additional proceeds from additional equity investments such as private placements under Regulation D and Regulation S under the Securities Act of 1933. We are working on a financing round, as stated above, to assist us in an effort to generate further equity investments within the next twelve months. The extent and timing of our future capital requirements will depend primarily upon the rate of our progress in the research and development of our technologies, our ability to enter into one or more licensing or partnership agreements with pharmaceutical companies, and the results of future clinical trials.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk from changes in interest rates which could affect our financial condition and results of operations. We have not entered into derivative contracts for our own account to hedge against such risk.

INTEREST RATE RISK

Fluctuations in interest rates may affect the fair value of financial instruments. An increase in market interest rates may increase interest payments and a decrease in market interest rates may decrease interest payments of such financial instruments. We have no debt obligations which are sensitive to interest rate fluctuations as all our notes payable have fixed interest rates, as specified on the individual loan notes.

ITEM 4. CONTROLS AND PROCEDURES
ITEM 4.CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation and supervision of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and determined that our disclosure controls and procedures were effective.
 
 
 
 
 
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

No changes of internal control over financial reporting were made in the three months ended September 30, 2010.March 31, 2012.

INHERENT LIMITATIONS ON EFFECTIVENESS OF CONTROLS

Our management, including our CEO and CFO, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected.

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 
 
 
 
PART II. 
OTHER INFORMATION

ITEM 1.
ITEM 1.  LEGAL PROCEEDINGS

Neither we, nor our wholly owned subsidiaries 6543 Luxembourg S.A., Mymetics S.A., Bestewil Holding B.V. nor its subsidiary Mymetics B.V. are presently involved in any litigation incident to our business except as follows:

Pursuant to our indemnification obligations under Delaware law, our charter and the prior consulting agreements with Christian Rochet and Ernst Luebke, respectively, we have paid a judgment for €173,000 entered against these two former officers and directors entered in November 2010 in a case styled Luebke Rochet / Serres – ref. 120494.  The lawsuit was brought in the Tribunal de Commerce in Lyon, France, by our former CEO, Dr. Pierre-Francois Serres, who sued Messrs. Rochet and Luebke for an alleged breach of a shareholders agreement in 1998. Mr. Serres brought this case against Messrs. Rochet and Luebke following the dismissal of the case he filed against us for an alleged unlawful termination of Mr. Serres by Messrs. Rochet and Luebke in 2003.  We appealed to this decision and the case has been dismissed in favour of Messrs. Rochet and Luebke. Mymetics has requested the return of the €173,000 funds.During 2011 these funds have been returned to Mymetics.

ITEM 1A. RISK FACTORS
ITEM 1A.RISK FACTORS

Not applicable.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
ITEM 3.DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
ITEM 4.MINE SAFETY DISCLOSURES

None.

ITEM 5.  OTHER INFORMATION
ITEM 5.OTHER INFORMATION

None.

ITEM 6.  EXHIBITS
ITEM 6.EXHIBITS
 
EXHIBIT
EXHIBIT
NUMBER
DESCRIPTION
 
31.1
Rule 13a-14(a)/15d-14(a) Certification of Chief
 Executive Officer31.2
31.2
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
 
32
Section 1350 Certification of Chief Executive Officerand Chief Financial Officer
 101.INS
33
Abbott: Termination letterInstance Document

101.SCHXBRL Taxonomy Extension Schema Document

101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document

101.PREXBRL Taxonomy Extension Presentation Linkbase Document
 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:  November 14, 2011 
MYMETICS CORPORATION
 
    
Dated:  May 11, 2012
By:/s/ Jacques-François MartinGrant Pickering 
  President and Chief Executive Officer 
    
 By:/s/ Ronald Kempers 
  Chief Financial Officer 
    
 By:/s/ Sylvain FleuryChris Henney 
  Chief Scientific OfficerChairman of the Board of Directors 
    
 By:/s/ Ernest Stern 
  Director